We are live on ! Find out more
FLNA

Filana Therapeutics

79 hedge funds and large institutions have $66.1M invested in Filana Therapeutics in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 36 increasing their positions, 13 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

177% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 13

122% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 9

16% more funds holding

Funds holding: 6879 (+11)

1.44% more ownership

Funds ownership: 27.35%28.79% (+1.4%)

15% less capital invested

Capital invested by funds: $77.4M → $66.1M (-$11.3M)

35% less call options, than puts

Call options by funds: $2.23M | Put options by funds: $3.45M

Holders
79
Holders Change
+11
Holders Change %
+16.18%
% of All Funds
1.4%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
20
Increased
36
Reduced
13
Closed
9
Calls
$2.23M
Puts
$3.45M
Net Calls
-$1.22M
Net Calls Change
-$4.56M

FLNA Hedge Fund Activity: Q4 2020 in Review

79 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Filana Therapeutics (FLNA) for Q4 2020, worth a combined $66.1M — down 15% from $77.4M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new FLNA positions and 9 closed out — a net gain of 11 holders — while 36 added to existing stakes and 13 trimmed.

The largest buyer was CAAS Capital Management, opening a new position worth an estimated $6.14M. The largest seller was Bleichroeder LP, cutting an estimated $3.57M.

  • 79 institutional investors held Filana Therapeutics (FLNA) as of Q4 2020, up from 68 in Q3 2020.
  • Funds reported $66.1M of Filana Therapeutics stock for Q4 2020, down 15% quarter-over-quarter.
  • 20 funds opened new Filana Therapeutics positions in Q4 2020 and 9 closed out, a net change of +11 holders.
  • The largest Filana Therapeutics buyer in Q4 2020 was CAAS Capital Management, an estimated $6.14M added.
  • The largest Filana Therapeutics seller in Q4 2020 was Bleichroeder LP, an estimated $3.57M sold.

Based on aggregated 13F filings for Q4 2020.